期刊文献+

非洛地平成品中杂质的分析和合成 被引量:6

Analysis and Synthesis of lmpurities in Felodipine
暂未订购
导出
摘要 根据非洛地平高效液相色谱的信息,利用气相色谱-质谱法,初步确定非洛地平成品中的两个杂质可能为同系物4-(2,3-二氯苯基)-1,4-二氢-2,6-二甲基-3,5-吡啶二羧酸甲酯(Ⅰ)和4-(2,3-二氯苯基)-1,4-二氢-2,6-二甲基-3,5-吡啶二羧酸乙酯(Ⅱ);并用化学方法合成了化合物(Ⅰ)和(Ⅱ),再经HPLC测定,通过比较它们之间的保留时间,进一步确证了非洛地平成品中的两个杂质分别为化合物(Ⅰ)和(Ⅱ)。 Based on the information of GC/MS of felodipine sample,we inferred that one of impurities(a) in felodipine sample was derivative methyl 1,4-dihydro-2,6-dimethyl-4-(2,3-dichlorophenyl)3,5-pyridinedicarboxylate(Ⅰ),the other(b) was derivative ethyl 1,4-dihydro-2,6-dimethyl-4-(2,3-dichlorophenyl)-3,5-pyridinedicarboxylate(Ⅱ).Compounds(Ⅰ) and(Ⅱ)were synthesized and compared with the impurities(a)and(b) in felodipine sample by HPLC method. Results showed that impurity(a)was identical to compound(Ⅰ) and impurity(b)was identical to compound(Ⅱ).
出处 《中国药科大学学报》 CAS CSCD 北大核心 1995年第2期65-67,共3页 Journal of China Pharmaceutical University
基金 国家医药管理局资助
关键词 非洛地平 高效液相色谱 杂质 钙拮抗剂 Felodiping Synthesis HPLC GC/MS lmpurity
  • 相关文献

同被引文献46

  • 1张婧,纪宪勇,孙翔,王杰.氯维地平的合成[J].中国医药工业杂志,2011,42(7):484-486. 被引量:5
  • 2Grodman AH, Vivas Y. New therapeutic perspectives with clevidipine: an ultra-short- acting intravenous Ca^2+ channel blocker [J]. Expert Opin Investig Drugs, 2007, 16(9) : 1449-1457.
  • 3Hjalmar AK, Fagared PL, Fjaras S, et al. Short-acting dihydropyridines: WO, 9512578 [P]. 1995-05-11. (CA 1995, 123: 313768).
  • 4Sorbera LA, Castaner J. Clevidipine: treatment of hypertension calcium channel blocker [J]. Drugs Future, 2004, 29 (2) : 105-111.
  • 5Mattson A, Svensson C, Thomblom K, et al. Manufacturing process: US, 6350877 [P]. 2002-02-26. (CA 2000, 133: 6161).
  • 6(Suh JJ, Hong YH. Synthesis of 1,4-dihydropyridine carboxylic acids(Ⅱ) [J]. YakhakHoechi, 1989, 33(4): 219-225.) CA 1990, 112: 235135t.
  • 7Antoncic L, Jazbec I, Kocjan D, et al. Process for the preparation of 2- (N-benzyl-N-methylamino) -ethylmethyl 2,6-dimethyl-4- (m-nitrophenyl) - 1,4-dihydropyridine-3,5- dicarboxylate and its hydrochloride salt: US, 4769465 [P]. 1988-09-06. (CA 1989, 110: 38901).
  • 8Boecker RH, Guengerich FP. Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis (alkoxycarbonyl) - 1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450 [J]. JMed Chem, 1986, 29(9): 1596-1603.
  • 9Grodman A H, Vivas Y. New therapeutic perspectives with clevidipine., an ultra-short-acting intravenous Ca^2+ channel blocker [J]. Expert Opin Investig Drugs, 2007, 16 (9): 1449-1457.
  • 10Sorbera L A, Castaner J. Clevidipine: treatm ent of hypertension calcium channel blocker [J]. Drugs Future, 2004, 29(2): 105-111.

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部